hotspot -WSS

hotspot

author：explore 2025-09-27 13:03:52 - browse：4637

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

WSS

A disappointing year of Humira biosimilars

Key House Republican on health care plans exit from Congress

Industry veterans launch new biotech VC with $310M

The Readout: Gilead, Bernie Sanders, and other pharma news

Ripples from Flovent's discontinuation is killing children with asthma

Cherokee Nation medical school graduates its first class

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Wildfire smoke exposes gaps in outdoor worker protections

HHS suspends federal funding for EcoHealth Alliance

Medical records are filled with copy

Readout LOUD podcast: How biotech is using artificial intelligence

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medical mystery: When a cough is not just a cough

Apple is now the first public company to be valued at $3 trillion

Hottest summer in 2,000 years puts focus on extreme heat, health

focus

Medicare threatens to cut off funding for HCA's Mission hospital

WuXi Biologics execs register to lobby as Congress comes for the company

Why did Pfizer dish out millions for a Super Bowl ad?

KalVista pill reduced swelling 'attacks' caused by genetic disease

Oak Street deal isn't the answer to health care's woes

CVS is willing to dump 10% of its Medicare Advantage members

knowledge

leisure time

focus

knowledge